Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) had its price objective decreased by equities researchers at Bank of America Corporation from $46.00 to $45.00 in a note issued to investors on Wednesday. The brokerage presently has a “buy” rating on the stock. Bank of America Corporation’s price objective suggests a potential upside of 20.16% from the company’s previous close.

A number of other brokerages have also issued reports on PCRX. Wedbush reissued an “outperform” rating and issued a $87.00 target price on shares of Pacira Pharmaceuticals in a research report on Wednesday, August 23rd. Mizuho restated a “buy” rating and set a $54.00 price target on shares of Pacira Pharmaceuticals in a research report on Wednesday, July 26th. ValuEngine lowered Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. BidaskClub cut Pacira Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 2nd. Finally, Cowen and Company reaffirmed a “hold” rating on shares of Pacira Pharmaceuticals in a research note on Friday, July 14th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have issued a buy rating to the company’s stock. Pacira Pharmaceuticals has an average rating of “Hold” and an average price target of $52.07.

Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) traded down 2.94% during midday trading on Wednesday, reaching $36.35. The company’s stock had a trading volume of 251,890 shares. The stock’s 50-day moving average is $37.03 and its 200-day moving average is $43.51. Pacira Pharmaceuticals has a one year low of $29.95 and a one year high of $58.95. The company’s market capitalization is $1.47 billion.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings data on Wednesday, August 2nd. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.06). The company had revenue of $70.90 million during the quarter, compared to analyst estimates of $73.37 million. Pacira Pharmaceuticals had a negative return on equity of 12.44% and a negative net margin of 23.36%. The business’s revenue was up 1.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.21 earnings per share. On average, equities analysts expect that Pacira Pharmaceuticals will post ($0.17) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/10/04/bank-of-america-corporation-lowers-pacira-pharmaceuticals-inc-pcrx-price-target-to-45-00.html.

In other news, Director Paul J. Hastings sold 1,044 shares of Pacira Pharmaceuticals stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $36.15, for a total transaction of $37,740.60. Following the completion of the sale, the director now directly owns 3,518 shares of the company’s stock, valued at approximately $127,175.70. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Kristen Marie Williams sold 3,461 shares of Pacira Pharmaceuticals stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $36.75, for a total transaction of $127,191.75. Following the sale, the chief accounting officer now directly owns 21,312 shares of the company’s stock, valued at $783,216. The disclosure for this sale can be found here. Over the last three months, insiders sold 33,390 shares of company stock worth $1,215,480. Insiders own 6.60% of the company’s stock.

A number of large investors have recently bought and sold shares of PCRX. BlackRock Inc. raised its stake in Pacira Pharmaceuticals by 28,922.7% in the first quarter. BlackRock Inc. now owns 3,183,787 shares of the company’s stock valued at $145,180,000 after buying an additional 3,172,817 shares in the last quarter. Columbus Circle Investors purchased a new stake in Pacira Pharmaceuticals during the 4th quarter worth about $56,726,000. HealthCor Management L.P. lifted its holdings in Pacira Pharmaceuticals by 63.1% during the 2nd quarter. HealthCor Management L.P. now owns 1,793,799 shares of the company’s stock worth $85,564,000 after buying an additional 693,799 shares during the last quarter. Lord Abbett & CO. LLC purchased a new stake in Pacira Pharmaceuticals during the 4th quarter worth about $43,764,000. Finally, Tudor Investment Corp ET AL purchased a new stake in Pacira Pharmaceuticals during the 1st quarter worth about $22,867,000.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.